Safety & immunogenicity of tgAAC09, a recombinant adeno-associated virus type 2 HIV-1 subtype C vaccine in India

Indian Journal of Medical Research

Volumn 132, Issue 8, 2010, Pages 168-175

  Mehendale, Sanjay ^a   Sahay, Seema ^a   Thakar, Madhuri ^a   Sahasrabuddhe, Sushant ^a   Kakade, Meghana ^a   Shete, Ashwini ^a   Shrotri, Aparna ^a   Spentzou, Aggeliki ^b   Tarragona, Tony ^b   Stevens, Gwynneth ^c   Kochhar, Sonali ^c   Excler, John Louis ^d   Fast, Pat ^d   Paranjape, Ramesh ^a  

^a NATIONAL AIDS RESEARCH INSTITUTE   (India)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^d UNAIDS   (Switzerland)

Author keywords

Adeno associated; Clinical trial; HIV candidate vaccine; Phase I; Safety; tgAACO9

Indexed keywords

DEOXYRIBONUCLEASE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PLACEBO; TGAAC09; UNCLASSIFIED DRUG; RECOMBINANT VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INDIAN; LOW DRUG DOSE; MALAISE; MALE; MUSCULOSKELETAL DISEASE; MYALGIA; NONHUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; ADENO ASSOCIATED VIRUS; DRUG TOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; INDIA;

ADULT; AIDS VACCINES; DEPENDOVIRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HIV-1; HUMANS; INDIA; MALE; VACCINES, SYNTHETIC;

EID: 77956073007     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. UNAIDS, 2009 AIDS Epidemic Update: Introduction. Available at: http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf, accessed on May 5, 2010.
2. National AIDS Control Organization (NACO), Department of AIDS Control, Government of India. Annual Report 2008-09. New Delhi: NACO; 2009.
3. Gangakhedkar RR, Bentley ME, Divekar AD, Gadkari D, Mehendale SM, Shepherd ME, et al. Spread of HIV infection in married monogamous women in India. JAMA 1997; 278: 2090-2.
4. Kunte A, Mishra V, Paranjape R, Mansukhani N, Padbidri V, Gonjari S, et al. HIV seroprevalence and awareness about AIDS among pregnant women in rural areas of Pune district, Maharashtra, India. Indian J Med Res 1999; 110: 115-22.
5. Mehendale SM, Rodrigues JJ, Brookmeyer RS, Gangakhedkar RR, Divekar AD, Gokhale MR, et al. Incidence and predictors of human immunodefciency virus type 1 seroconversion in patients attending sexually transmitted disease clinics in India. J Infect Dis 1995; 172: 1486-91.
6. Mehendale SM, Shepherd ME, Divekar AD, Gangakhedkar RR, Kamble SS, Menon PA, et al. Evidence for high prevalence & rapid transmission of HIV among individuals attending STD clinics in Pune, India. Indian J Med Res 1996; 104: 327-35.
7. Dworkin SL, Ehrhardt AA. Going beyond "ABC" to include "GEM": critical refections on progress in the HIV/AIDS epidemic. Am J Public Health 2007; 97: 13-8.
8. Marsden MD, Zack JA. Eradication of HIV: current challenges and new directions. J Antimicrob Chemother 2009; 63: 7-10.
9. McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis 2010; 23: 26-31.
10. Kulczycki A, Kim DJ, Duerr A, Jamieson DJ, Macaluso M. The acceptability of the female and male condom: a randomized crossover trial. Perspect Sex Reprod Health 2004; 36: 114-9.
11. Bryant J, Baxter L, Hird S. Non-occupational postexposure prophylaxis for HIV: a systematic review. Health Technol Assess 2009; 13: 1-60.
12. Hopkins DR. Smallpox: ten years gone. Am J Public Health 1988; 78: 1589-95.
13. Werner GH. Historical aspects of some infectious diseases: is their gradual eradication utopian? Rev Hist Pharm (Paris) 2009; 57: 173-92.
14. International AIDS Vaccine Initiative, New York. Available at: www.iavireport.org/trialsdb, accessed on January 12, 2010.
15. Mehendale S, Van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson PR, et al. A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses 2008; 24: 873-80.
16. Gadkari DA, Moore D, Sheppard HW, Kulkarni SS, Mehendale SM, Bollinger RC. Transmission of genetically diverse strains of HIV-1 in Pune, India. Indian J Med Res 1998; 107: 1-9.
17. Duerr A, Wasserheit JN, Corey L. HIV vaccines: New frontiers in vaccine development. Clin Infect Dis 2006; 43: 500-11.
18. Corey L, Mcelrath MJ, Weinhold K, Matthews T, Stablein D, Graham B, et al. Cytotoxic T cell and neutralizing antibody responses to human immunodefciency virus type 1 envelope with a combination vaccine regimen. J Infect Dis 1998; 177: 301-9.
19. Graham BS, Belshe RB, Clements ML, Dolin R, Corey L, Wright PF, et al. Vaccination of vaccinia-naive adults with human immunodefciency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J Infect Dis 1992; 166: 244-52.
20. Goepfert PA, Horton H, McElrath MJ, Gurunathan S, Ferrari G, Tomaras GD, et al. High-dose re-combinant canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 2005; 192: 1249-59.
21. AIDS Vaccine Evaluation Group 022 Protocol Team. The Cellular and humoral immune responses to a canarypox vaccine containing human immunodefciency virus type 1 Env, Gag, and Pro in combination with RGP120. J Infect Dis 2001; 183: 563-70.
22. Gupta K, Hudgens M, Corey L, McElrath MJ, Weinhold K, Montefori DC, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defc Syndr 2002; 29: 254-61.
23. Vardas E, Kaleebu P, Bekker L, Hoosen A, Chomba E, Johnson P, et al. A phase 2 study to evaluate the safety and immunogenicity of a recombinant adeno-associated virus HIV vaccine. Seattle, Washington (2007); Posted as Notes: 20 August on the EMMES Corporation website https://secure.emmes.com/emmesweb/biblio/phase-2-study-evaluate-safety-and-immunogenicity-recombinant-adeno-associated-virus-hiv-vacci, accessed on January 14, 2010.
24. Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, et al. Novel adeno-associated virus vector vaccine restricts replication of Simian immunodefciency virus in macaques. J Virol 2005: 79: 955-65.
25. Phambili trial - factsheet from the South African AIDS Vaccine Initiative. Available at: http://www.hvtn.org/media/pr/PhambiliSAAVIstatement.pdf, accessed on January 12, 2010.
26. Kim D, Elizaga M, Duerr A. HIV vaccine effcacy trials: towards the future of HIV prevention. Infect Dis Clin North Am 2007; 21: 201-17.
27. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008; 205: 7-12.
28. Cohen J. AIDS research. Did Merck's failed HIV vaccine cause harm? Science 2007; 318: 1048-9.
29. Lu S. Human versus HIV: round 2 defeat in AIDS vaccine development. Expert Rev Vaccines 2008; 7: 151-3.
30. Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Joseph Chiu, Robert Paris, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361: 2209-20.